Finding a sweet spot for leptin
- PMID: 35590217
- DOI: 10.1016/j.medj.2021.06.008
Finding a sweet spot for leptin
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem that progresses to serious liver disease in some patients and for which there are no FDA-approved therapies. In this issue of Med, Akinci et al.1 present encouraging preliminary data showing that treatment with recombinant leptin has beneficial effects on NAFLD.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests R.J.B. has received in-kind research support (donation of metreleptin for investigator-initiated studies) from Amgen, Amylin Pharmaceuticals, Bristol Myers Squibb/Astra Zeneca, Aegerion Pharmaceuticals, and Amryt Pharma, and serves in an unpaid advisory capacity for Amryt Pharma. M.L.R. declares no competing interest.
Comment on
-
Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.Med. 2021 Jul 9;2(7):814-835. doi: 10.1016/j.medj.2021.04.001. Epub 2021 May 12. Med. 2021. PMID: 35291351 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
